- Home
- LEXX vs DTIL Comparison
LEXX vs DTIL Comparison
Compare LEXX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- DTIL
- Stock Information
- Founded
- LEXX 2004
- DTIL 2006
- Country
- LEXX Canada
- DTIL United States
- Employees
- LEXX N/A
- DTIL N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- DTIL Health Care
- Exchange
- LEXX Nasdaq
- DTIL Nasdaq
- Market Cap
- LEXX 38.9M
- DTIL 44.1M
- IPO Year
- LEXX N/A
- DTIL 2019
- Fundamental
- Price
- LEXX $2.23
- DTIL $4.72
- Analyst Decision
- LEXX Strong Buy
- DTIL Strong Buy
- Analyst Count
- LEXX 2
- DTIL 2
- Target Price
- LEXX $11.00
- DTIL $39.50
- AVG Volume (30 Days)
- LEXX 202.7K
- DTIL 112.5K
- Earning Date
- LEXX 01-10-2025
- DTIL 11-04-2024
- Dividend Yield
- LEXX N/A
- DTIL N/A
- EPS Growth
- LEXX N/A
- DTIL N/A
- EPS
- LEXX N/A
- DTIL 1.45
- Revenue
- LEXX $464,278.00
- DTIL $75,096,000.00
- Revenue This Year
- LEXX $20.39
- DTIL $50.33
- Revenue Next Year
- LEXX $113.25
- DTIL N/A
- P/E Ratio
- LEXX N/A
- DTIL $2.44
- Revenue Growth
- LEXX 105.24
- DTIL 43.62
- 52 Week Low
- LEXX $1.20
- DTIL $4.13
- 52 Week High
- LEXX $6.85
- DTIL $19.43
- Technical
- Relative Strength Index (RSI)
- LEXX 47.23
- DTIL 32.40
- Support Level
- LEXX $2.00
- DTIL $4.13
- Resistance Level
- LEXX $2.54
- DTIL $6.18
- Average True Range (ATR)
- LEXX 0.24
- DTIL 0.49
- MACD
- LEXX -0.00
- DTIL -0.09
- Stochastic Oscillator
- LEXX 27.06
- DTIL 21.45
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.